IGC Pharma (IGC) Receivables - Other (2016 - 2025)
IGC Pharma (IGC) has disclosed Receivables - Other for 14 consecutive years, with $670000.0 as the latest value for Q3 2025.
- On a quarterly basis, Receivables - Other fell 2.19% to $670000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $670000.0, a 2.19% decrease, with the full-year FY2025 number at $680000.0, down 0.87% from a year prior.
- Receivables - Other was $670000.0 for Q3 2025 at IGC Pharma, down from $680000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $951000.0 in Q1 2023 to a low of $354000.0 in Q2 2022.
- A 5-year average of $647368.4 and a median of $680000.0 in 2025 define the central range for Receivables - Other.
- Peak YoY movement for Receivables - Other: skyrocketed 168.64% in 2023, then decreased 28.22% in 2024.
- IGC Pharma's Receivables - Other stood at $382000.0 in 2021, then soared by 96.6% to $751000.0 in 2022, then increased by 25.97% to $946000.0 in 2023, then fell by 28.22% to $679000.0 in 2024, then dropped by 1.33% to $670000.0 in 2025.
- Per Business Quant, the three most recent readings for IGC's Receivables - Other are $670000.0 (Q3 2025), $680000.0 (Q2 2025), and $680000.0 (Q1 2025).